Oncarin · A scientifically proven Microbiome immunotherapy for the treatment of colorectal cancer

Following 30 years of research, ZMD has developed ONCARIN; an immunotherapy treatment for the treatment and to boostto immune system of patients with colorectal cancer. The treatment consists of special developed capsules containing alyophilized mixture of live bacteria (colon flora) with a high oncolytic activity. ONCARIN has the unique ability to both inducecancer cell destruction and activate the immune system. Furthermore the technology allows for an easy synthesis andmanufacture enabling the commercialization of a cost-effective product (90% lower than competitor’s prices). No otheroncologic drug, currently marketed, is able to address therapy effectiveness, absence of side effects, and healthcare costsavings.In addition, Oncarin can be easily implemented for a wide range of immune conditions including cancer, Crohn’sdisease, colities and immune system disorders after long-term treatment with antibiotics. This will improve patient outcomesand greatly reduce healthcare costs. Moreover, ONCARIN costs 90% less than current solutions. ZMD will exclusivelylicense the further development and commercialization of ONCARIN to a pharmaceutical company. Oncarin now has a TRL6, since successfully completing proof of concept in animal models. The next step to advance TRL is to conduct a phase Itrial in order to demonstrate safety and pharmaceutics of Oncarin. Z.M.D Medical Ltd is part of ZMD group ,which includesZMD Diagnostics Ltd. ZMD Medical develops and commercializes therapeutic remedies to cure cancer of all types using theimmune system- first focus- colorectal cancer. Z.M.D Medical has set a goal to produce the drug to rehabilitate distressedcolon microflora in order to eliminate cancer from patients’ immune systems. Barak Zigdon, an MBA with significantentrepreneurial experience, leads the team. The team boasts more than 30 years of experience in Cancer research andproduct development.